ABBV/ENTA—Agree with your comments vis-à-vis cirrhotic patients and the importance of the TURQUOISE-2 study to the overall commercial uptake of the regimen.
However, I don’t fully understand why you think the non-ribavirin arms of PEARL-2/3/4 are so easy to handicap. For the record, what are your expectations for each of these trial arms? T.i.a.
Market Data 
Markets 
AI
